Acquisition of FOSLEVO+FOSCARBI SC 240+12MG/ML 10ML PER, from Lab. Abbvie, for ULSASI, for the year 2026

This tender is for the specific acquisition of a pharmaceutical product: FOSLEVO+FOSCARBI SC with a concentration of 240+12MG/ML in a 10ML PER format. The medication is to be sourced from the laboratory Abbvie. The intended recipient or user of this medication is ULSASI (Unidade Local de Saúde do Alto Minho, S.A. or similar local health unit). The procurement is planned for the year 2026. This is a direct procurement or a call for offers for a specific, named drug, likely for use within the Portuguese National Health Service (SNS) or a related healthcare institution. The tender specifies the exact pharmaceutical name, dosage, concentration, volume, and manufacturer, indicating a need for a particular treatment. Interested suppliers must be able to provide this exact product, meeting all regulatory and quality standards required for pharmaceutical distribution. The acquisition aims to ensure the availability of this essential medication for patients under the care of ULSASI throughout 2026.

This is a supplies contract in the health and medical services, trade and industry and general supplies sectors. Located in Portugal, Europe, this opportunity is open to firms and consortiums, with an estimated budget of EUR 109,749.

Published through base_gov_pt, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.